Refine by
Biopsy Articles & Analysis: Older
227 news found
Carolina Reduzzi, an Assistant Professor of Cancer Biology Research in Medicine and Director of the Liquid Biopsy Platform of the Englander Institute for Precision Medicine (EIPM) at Weill Cornell Medicine. ...
Tennessee Oncology started using SOPHiA GENETICS in early 2024, when it began to validate the liquid biopsy test MSK-ACCESS® powered with SOPHiA DDM™ alongside the SOPHiA DDM™ Hereditary Cancer Solution. ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced a new milestone in the global introduction of the liquid biopsy test MSK-ACCESS® powered with SOPHiA DDM™, first announced in October 2023. ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that the company is joining the European Liquid Biopsy Society (ELBS), a prestigious network consisting of partners from academia and industry with the common goal of making liquid biopsy tests part of the routine standard of ...
Results from testing of POTENTIATE trial participants’ biopsy samples will be used to further analyze clinical activity of the investigational drug BBI-355 in specific patient populations. ...
About Carcinotech Carcinotech is revolutionising cancer research by manufacturing 3D-printed micro-tumours using patient-derived biopsies, primary cells, immune cells, and cancer stem cells. Our advanced offering provides a platform for rapid, ethical, and accurate drug screening, pre-clinical, and personalised medicine testing. Carcinotech’s goal is to accelerate drug ...
ByCELLINK
Dr. Ali Tinazli is the CEO of lifespin.health and has 15+ years in Fortune 100 corporate strategy and entrepreneurship (SONY, HP). Obesity rates continue to climb alongside a $254.9 billion global weight loss products and services market. Supplements, smartphone weight loss apps, diet plans and exercise programs are widely available to consumers, yet the World Obesity Federation projects that 1 ...
Combining 3-D ultrasound and MRI technology can accurately map biopsy samples. Technological advancements in imaging mean swift and accurate diagnoses of PC with less ambiguity than previously encountered. ...
The project is leveraging the fully integrated BioMark’s metabolomic liquid biopsy platform to develop a safe, effective, and affordable drug biomarker test to assess and monitor response to therapy which could provide both clinician and patient with an accurate and easy way to perform relapse surveillance and therapeutic monitoring more effectively. ...
Pak told the audience the microfluidic device can keep biopsied cancer cells alive for three days in a simulated natural environment that enables scientists to measure their behavior and response to multiple drug combinations. ...
One major challenge they faced was that some of the samples, which were derived from patient biopsies, did not have large enough counts of cancer cells to be useful to the researchers. “This was very unfortunate because these patients were volunteering to give us biopsy samples, but we were only able to analyze about half of them,” Pak says. ...
Current standard of care involves invasive BM biopsies to understand disease pathology and decide on treatment strategies. ...
The miR Sentinel™ Prostate Cancer Test is a standalone, non-invasive liquid biopsy urine test that can, from a single urine specimen, accurately detect molecular evidence of prostate cancer and, if cancer is detected, classify the severity, or the risk grade, of the malignancy. ...
We report that opioids from the inflamed colon activate δ-opioid receptors (DOPr) in endosomes of nociceptors. Biopsy samples of inflamed colonic mucosa from patients and mice with colitis released opioids that activated DOPr on nociceptors to cause a sustained decrease in excitability. ...
With this partnership, the companies will offer an optimized workflow for a wide range of applications including liquid biopsy, sentinel pathogen testing, infectious disease assays, overall cancer research and drug discovery. Representative data of the liquid biopsy workflow will be presented at the American Association for Cancer Research (AACR) Annual Meeting ...
From a single whole slide H&E biopsy image, in seconds 4D Path can identify any cancer type (pan cancer), its prognostically significant subtypes, variants, grades, and molecular profile with overexpression status as well as benign lesions. ...
The latest round will support legal and consulting costs as well as continued expansion of its research, team, infrastructure, data acquisition and business development. 4D Path’s patented precision oncology platform unveils previously hidden data to instantly provide biomarker profiling and stratification directly from a single H&E biopsy image. By eliminating the ...
(“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce several updates from ongoing clinical trial using the Company’s liquid biopsy test for early cancer detection and monitoring of lung cancer. ...
BioMark is currently pursuing two clinical trials using this liquid biopsy platform that can improve identification and assessing response to treatment for patients with lung cancer and glioblastoma. ...
(“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today the publication of a preclinical study demonstrating therapeutic capabilities of its SAT1 cancer marker in glioblastoma (GB) cells using an ionizable lipid nanoparticle. ...